Casey Burton

Dr. Casey Burton

Phelps Health, Missouri University of Science and Technology, Rolla, MO, USA
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2020 in The Neuroscientist
Verified
Journal Article
Open access
PDF file
KDKempuraj Duraisamy
Kempuraj Duraisamy
GSGovindhasamy Pushpavathi Selvakumar
Govindhasamy Pushpavathi Selvakumar
MAMohammad Ejaz Ahmed
Mohammad Ejaz Ahmed
SRSudhanshu P. Raikwar
Sudhanshu P. Raikwar
RTRamasamy Thangavel
Ramasamy Thangavel
AZAsgar Zaheer
Asgar Zaheer
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new pandemic infectious disease that originated in China. COVID-19 is a global public health emergency of international concern. COVID-19 causes mild to severe illness with high morbidity and mortality, especially in preexisting risk groups. Therapeutic options are now limited to COVID-19. The hallmark of COVID-19 pathogenesis is the cytokine storm with elevated levels of interleukin-6 (IL-6), IL-1β, tumor necrosis factor-alpha (TNF-α), chemokine (C-C-motif) ligand 2 (CCL2), and granulocyte-macrophage colony-stimulating factor (GM-CSF). COVID-19 can cause severe pneumonia, and neurological disorders, including stroke, the damage to the neurovascular unit, blood-brain barrier disruption, high intracranial proinflammatory cytokines, and endothelial cell damage in the brain. Mast cells are innate immune cells and also implicated in adaptive immune response, systemic inflammatory diseases, neuroinflammatory diseases, traumatic brain injury and stroke, and stress disorders. SARS-CoV-2 can activate monocytes/macrophages, dendritic cells, T cells, mast cells, neutrophils, and induce cytokine storm in the lung. COVID-19 can activate mast cells, neurons, glial cells, and endothelial cells. SARS-CoV-2 infection can cause psychological stress and neuroinflammation. In conclusion, COVID-19 can induce mast cell activation, psychological stress, cytokine storm, and neuroinflammation.

14 March 2019 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Casey BurtonCasey Burton
Casey Burton
YMYinfa Ma
Yinfa Ma
Background: The development of effective screening methods for early cancer detection is one of the foremost challenges facing modern cancer research. Urinary metabolomics has recently emerged as a potentially transformative approach to cancer biomarker discovery owing to its noninvasive sampling characteristics and robust analytical feasibility.Objective: To provide an overview of new developments in urinary metabolomics, cover the most promising aspects of hyphenated techniques in untargeted and targeted metabolomics, and to discuss technical and clinical limitations in addition to the emerging challenges in the field of urinary metabolomics and its application to cancer biomarker discovery.Methods: A systematic review of research conducted in the past five years on the application of urinary metabolomics to cancer biomarker discovery was performed. Given the breadth of this topic, our review focused on the five most widely studied cancers employing urinary metabolomics approaches, including lung, breast, bladder, prostate, and ovarian cancers.Results: As an extension of conventional metabolomics, urinary metabolomics has benefitted from recent technological developments in nuclear magnetic resonance, mass spectrometry, gas and liquid chromatography, and capillary electrophoresis that have improved urine metabolome coverage and analytical reproducibility. Extensive metabolic profiling in urine has revealed a significant number of altered metabolic pathways and putative biomarkers, including pteridines, modified nucleosides, and acylcarnitines, that have been associated with cancer development and progression.Conclusion: Urinary metabolomics presents a transformative new approach toward cancer biomarker discovery with high translational capacity to early cancer screening.

1 January 2016 in Clinica Chimica Acta
Verified
Journal Article
Closed access
Casey BurtonCasey Burton
Casey Burton
YDYongbo Dan
Yongbo Dan
ADAriel Donovan
Ariel Donovan
KLKun Liu
Kun Liu
HSHonglan Shi
Honglan Shi
CBCynthia P. Bosnak
Cynthia P. Bosnak

24 June 2020 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
KDKempuraj Duraisamy
Kempuraj Duraisamy
MAMohammad Ejaz Ahmed
Mohammad Ejaz Ahmed
GSGovindhasamy Pushpavathi Selvakumar
Govindhasamy Pushpavathi Selvakumar
RTRamasamy Thangavel
Ramasamy Thangavel
SRSudhanshu P. Raikwar
Sudhanshu P. Raikwar
AZAsgar Zaheer
Asgar Zaheer
Traumatic brain injury (TBI) is one of the major health problems worldwide that causes death or permanent disability through primary and secondary damages in the brain. TBI causes primary brain damage and activates glial cells and immune and inflammatory cells, including mast cells in the brain associated with neuroinflammatory responses that cause secondary brain damage. Though the survival rate and the neurological deficiencies have shown significant improvement in many TBI patients with newer therapeutic options, the underlying pathophysiology of TBI-mediated neuroinflammation, neurodegeneration, and cognitive dysfunctions is understudied. In this study, we analyzed mast cells and neuroinflammation in weight drop-induced TBI. We analyzed mast cell activation by toluidine blue staining, serum chemokine C-C motif ligand 2 (CCL2) level by enzyme-linked immunosorbent assay (ELISA), and proteinase-activated receptor-2 (PAR-2), a mast cell and inflammation-associated protein, vascular endothelial growth factor receptor 2 (VEGFR2), and blood-brain barrier tight junction-associated claudin 5 and Zonula occludens-1 (ZO-1) protein expression in the brains of TBI mice. Mast cell activation and its numbers increased in the brains of 24 h and 72 h TBI when compared with sham control brains without TBI. Mouse brains after TBI show increased CCL2, PAR-2, and VEGFR2 expression and derangement of claudin 5 and ZO-1 expression as compared with sham control brains. TBI can cause mast cell activation, neuroinflammation, and derangement of tight junction proteins associated with increased BBB permeability. We suggest that inhibition of mast cell activation can suppress neuroimmune responses and glial cell activation-associated neuroinflammation and neurodegeneration in TBI.

21 September 2020 in Neurotoxicity Research
Verified
Journal Article
Closed access
PDF file
KDKempuraj Duraisamy
Kempuraj Duraisamy
MAMohammad Ejaz Ahmed
Mohammad Ejaz Ahmed
GSGovindhasamy Pushpavathi Selvakumar
Govindhasamy Pushpavathi Selvakumar
RTRamasamy Thangavel
Ramasamy Thangavel
SRSudhanshu P. Raikwar
Sudhanshu P. Raikwar
AZAsgar Zaheer
Asgar Zaheer